Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389049 · ClinicalTrials.gov registry record
Genetics of Primary Ciliary Dyskinesia
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 320
- Enrollment target
NCT02389049 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 320 participants.
The verdict
NCT02389049 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 320 participants
- Enrollment target
Study Summary
This study is designed to study DNA sequencings for mutations in a research genetic test panel of genes (which contains all 32 known and/or published genes associated with PCD). The study aims to show that about 70% of PCD patients have biallelic mutations in one of these genes. This project will enroll patients who have already had a clinical evaluation, and have clinical features consistent with PCD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389049
The ClinicalTrials.gov registry entry for NCT02389049 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02389049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389049 about?
NCT02389049 is a clinical study titled "Genetics of Primary Ciliary Dyskinesia". This study is designed to study DNA sequencings for mutations in a research genetic test panel of genes (which contains all 32 known and/or published genes associated with PCD). The study aims to show that about 70% of PCD patients have biallelic mutations in one of these genes. This project will en...
What is the current status of trial NCT02389049?
This trial is currently completed. The enrollment target is 320 participants. The study started on 2015-02. Estimated completion is 2018-07.
Who is sponsoring clinical trial NCT02389049?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.